Index

abnormal illness in cancer patients 62
diagnosis 63–4
management and prognosis 64
prevalence 62–3
access to care and services
elderly sufferers 156–7
undeserved and minority populations 166
behaviour change strategies 167–8
high-risk groups 166–7
improving uptake 168–9
acupuncture 49
acute brain failure 55
acute confusional state 55
acute stress disorder (ASD) 143
parents of childhood patients and survivors 146–7
adenomatous polyposis coli (APC) gene mutation 227
adjustment disorders 61–2
diagnosis 62
management and prognosis 62
prevalence 62
adolescent cancer sufferers 142–3
Advance Care Planning (ACP) 204–5
Africa 305–6
palliative and psychosocial care 306–7
psycho-oncology services 307
age-related impact of cancer
see life-stage approach
alcoholism 65
alone-ness, existential challenge 286
alprazolam
anxiety disorders 61
Alzheimer’s Disease Neuroimaging Initiative (ADNI) 80
American Cancer Society 298
amitriptyline 111, 115
pharmacological issues 113
palliative care 60
anal intercourse 45
anhedonia 59
anticholinergic side-effects 120
anticipatory anxiety 143–4
anticipatory nausea and vomiting (ANV) 65
anticonvulsants 121–2
antidepressants 59–60
classification 114–16
indications in oncology settings 113–14
interactions 112–13
overview 110–12
screening, monitoring and cautions for patients 116–17
special considerations in oncology settings 116
antipsychotic medications 117
classification 118–19
drug–drug interactions 120–1
indications for in oncology settings 117
anxiety disorders 118
delirium 117–18
depression 118
hiccups 118
nausea 118
psychosis 118
sleep disorders 118
palliative care 60
side effects and safety monitoring anticholinergic side-effects 120
cardiotoxicity 119
endocrine side-effects 119–20
extrapyramidal symptoms (EPS) 119
haematological side-effects 120
hepatic side-effects 120
neuroleptic malignant syndrome (NMS) 119
sedation 120
seizure 120
anxiety and anxiety disorders 60
anticipatory anxiety 143–4
antidepressants 114
antipsychotic medication 118
conditioned anxiety 143–4
diagnosis 60–1
end-of-life (EOL) care 251
assessment 251–2
prevalence 251
management and prognosis 61
case study 104–5
measure 23
comparison data 25–6
cultural considerations 28–33
overall performance 27–8
reliability 24–5
screening 26–7
summary of evaluative information 24
validity 25
pre-school children 141–2
prevalence 60
risk factors 61
symptoms 61
anxiety
anxiolytics 121
Index

apolipoprotein E (ApoE) 75
aripiprazole 117
delirium 57
Asia
Reach to Recovery 303–5
assisted reproduction technology (ART) 48
assisted suicide 260–1
atheism 290
attachment (between children and caregivers) 141
atypical antidepressants 112, 115
Australia 302
agencies and institutions
advocating psycho-oncology 4
Breast Cancer Network Australia (BCNA) 303
Cancer Voices Australia (CVA) 303
care policies 11–12
immigration issues 12–13
interpreters 14
Prostate Cancer Foundation of Australia (PCFA) 302–3
Beck Depression Inventory (BDI) 23, 24
Beck Depression Inventory II (BDI-II) 23, 24
Beck Depression Inventory-Short Form (BDI-SF) 23, 24
bedside communication 16–17
beliefs about cancer 177
Benefit/Burden Scale for Children (BBSC) 146
benzodiazepines
adjustment disorders 62
anticipatory nausea and vomiting (ANV) 65
anxiety disorders 61
indications in oncology settings 121
bereavement see grief and bereavement
beta-blockers
anxiety disorders 61
BETTER model for infertility 50, 51
bioethical challenges 208
case study 199–200
cross-cultural communication 203–4
culture 200–1
culture and oncology 201–2
culture, health and illness 202–3
ethical duty of cultural competence 207
family caregiving 205–6
global perspective 208
key points 209
overcoming language and cultural barriers 206–7
palliative (PC) and end-of-life (EOF) care 204–5
survivorship care 203
bladder cancer 44–5
brain
impact of chemotherapy on structure and function 76
breast cancer 42–4
BRCA1 gene mutation 225, 227, 232
BRCA2 gene mutation 232
case study 129
Hong Kong 172–3
prevalence 127
Breast Cancer Network Australia (BCNA) 303
Brief Symptom Inventory (BSI) 23, 24
Brief Symptom Inventory-18 (BSI-18) 23, 24
Buddhism 282–3
Bulgaria
cancer care spending 298
bupropion 112
pharmacological issues 113
side effects 115
side effects 116
buspirone
anxiety disorders 61
Calgary Symptoms of Stress Inventory (C-SOSI) 23, 24
CALM therapy 160
Canada
agencies and institutions
advocating psycho-oncology 4
childhood cancer studies 144–5
distress in cancer patients 173
cancer
deaths 3
incidence 3
outcomes
communication, importance of 12
patient failure to adapt 4
prevalence of heritable conditions 223
cancer survivorship 127–8, 243–4
background 237–8
care team organization 242–3
clinical case study 244
key points 245
recovery trajectory after treatment end
contributors to psychosocial outcomes 240
psychosocial distress and recovery 238–40
symptoms 240–1
sociocultural and developmental factors
experience of cancer 241–2
experience of cancer in developmental context 242
Cancer Voices Australia (CVA) 303
capacity 158
carbamazepine 122
cardiotoxicity 119
carmustine 77
catechol-o-methyl transferase (COMT) 75
Center for Epidemiologic Studies Depression Scale (CES-D) 23, 24
chemotherapy
cognitive change 73
impact on brain structure and function 76
sexual dysfunction 42
Childhood Cancer Survivors Study (CCSS) 144, 145, 146
siblings of childhood patients and survivors 147
children see pediatric psycho-oncology
Children’s Oncology Group (COG) 144
China
patient–clinician roles 13
chlorpromazine 117
hypotension 119
seizure risk 120
Index

314

314

314

314

distress (Continued)
summary of evaluative information 24
validity 25
Distress Thermometer (DT) 23, 24
translations 30–2
divalproex sodium 122
dopamine (DA) 75
Dual Process Model of grief 273
duloxetine 111
depression 59
pharmacological issues 113
dyspareunia 42
dysphoria 58
Edinburgh Postnatal Depression Scale (EPDS) 23, 24
Edmonton Symptom Assessment Scale (ESAS) 23, 24
endocrine side-effects 119–20
end-of-life (EOL) care 203–4, 249, 266
see also palliative care (PC)
clinical case study 267
common disorders
anxiety 251–3
depression 253–5
delirium 261
assessment and reversibility 261–2
experience for patients, families and staff 261
interventions 262–3
prevalence 261
early death 255
assisted suicide 260–1
desire for hastened death (DHD) 259–60
suicide 255–7
suicide ideation frequency 257–9
emerging psychotherapeutic interventions
cross-cultural issues 266
demoralization 264–5
dignity model for terminally ill 265
dignity-conserving care 265
meaning-centred psychotherapy (MCP) 264
older adults 265–6
spiritual suffering therapy 264

ethical challenges 204–5
‘good’ death 250–1
key points 266–7
palliative care (PC)
definition 250
historical perspective 249–50
models/programmes of care delivery 250
psychotherapy interventions 263
existential therapies 263–4
group psychotherapy 264
individual psychotherapies 263
epidemiology 3–4
erectile dysfunction 41, 44
Erickson’s life stage developmental theory 159
esitalopram 111
metabolism 114
pharmacological issues 113
eszopiclone 121
ethical considerations see bioethical challenges

Ethiopian families in Israel 194–5
Europe
agencies and institutions
advocating psycho-oncology 5
cancer care provision 298
patient advocacy movement 299
psycho-oncology 299–300
European Cancer Patient Coalition 297
existential distress 286
existential therapies 263–4
extrapyramidal symptoms (EPS) 119
Familial Adenomatous Polyposis (FAP) 227, 232
families 187–8
caregiving 161
bioethics 205–6
childhood patients and survivors
parents 146–7
siblings 147
communications 13–14
case study 15
culture and care 189, 195–6
family-focused interventions 148
illness within 188–9
key points 196
Middle Eastern experiences 189–90
clinical cases 192, 194, 195
Ethiopians 194–5
Muslim families 193–4
ultra-Orthodox Jewish families 190–3
fetalism 171
fatigue 62–3
antidepressants 114
management 64
fertility preservation 48
5-fluorouracil 77
fluoxetine 111
metabolism 114
pharmacological issues 113
Folkman’s cognitive coping paradigm 159
freedom, existential challenge 286
frigidity 42
functional magnetic resonance imaging (fMRI)
impact of chemotherapy on brain 76

gabapentin 122
gastrointestinal cancer 44–5
gender see sexuality and gender
general anxiety disorder (GAD) 60
antidepressants 114
General Health Questionnaire-12 (GHQ-12) 23, 24
General Health Questionnaire-28 (GHQ) 23, 24
genetic counselling and testing 232–3
background 223–4
key points 233
cross-cultural approaches 228–30
case study 231–2
cognitive behavioural (CBT) strategies 230
psychodynamic approaches 230–1
psychological risk factors 229
psychosocial and psychotherapeutic interventions 229
psychosocial issues 224–5
case studies 225, 227
family impacts 226–7
inconclusive test results 226
socio-cultural issues 228
testing negative 226
testing positive for genetic mutation 225–6

genetic risks 166–7
Germany
cancer care spending 298
cancer rehabilitation process 129–30
‘good’ death 250–1
grief and bereavement 271
after death 275
case study 277–8
expressing loss and acknowledging death 276
facing new/difficult situations 276
maintaining connection with deceased 276–7
self-care activities 276
sleep disruption 277
background 271–2
before death 274
cultural guidelines 278–9
key points 279
major issues 272
caring for bereaved 274–8
prolonged grief 274
understanding grief 272–4
nature of 272
Dual Process Model 273
education about 276
normal grief 272–3
resolution 273
risk factors for poor outcomes 273–4
wave-like pattern 273
psychological strategies 275–8
self-care for clinicians 279
strategies 279
gynaecological tumours 42–4
hepatitic side-effects 120
heredity non-polyposis colon cancer (HNPPC) 233
hiccups
antipsychotic medication 118
high-risk groups 166–7
Hinduism 283
spiritual approach 290
hydroxyzine
anxiety disorders 61
hyperactive delirium 56
hypnotics 121
imipramine 111, 115
pharmacological issues 113
immigration and communication issues 12–13
Impact of Event Scale (IES) 23, 24
in vitro fertilization (IVF) 48, 49
in vitro fertilisation (IVF) 49
tissue banking and fertility preservation 48
suggestions for clinicians 50–1
informed consent 13
integrated interdisciplinary patient-centred care 94
current cancer care 84
interdisciplinary teams 83
key points 94
major issues
model programmes 88–90
pain versus distress 84–8
Screening for Distress 88
whole-person-centred care 90–4
patient-reported concerns 86
problem-related distress 87
whole-person cancer care 83–4
Integrated Symptom Relief Service 90
international agencies and institutions 4–5
International Cancer and Cognition Task Force (ICCTF) 78–80
methodological recommendations 79
recommended neurophysiological tests 79
International Classification of Functioning, Disability and Health (ICF) 128–9
international perspective on psycho-oncology 297–8, 307–8
Africa 305–6
palliative and psychosocial care 306–7
psycho-oncology services 307
Asia
Reach to Recovery 303–5
Australia 302
Breast Cancer Network Australia (BCNA) 303
Cancer Voices Australia (CVA) 303
Prostate Cancer Foundation of Australia (PCFA) 302–3
Europe
inequalities in cancer care 298–9
patient advocacy movement 299
psycho-oncology 299–300
key points 308
USA
community response to IOM Report 301
future provision 301–2
IOM Report 300–1
Index

International Psycho-Oncology Society (IPOS) 5
formation of ICCTF 78–80
handbook of psychotherapies 101
Internet resources
online lectures 101
interpreters for patient communication 14
Islam 283
female sexuality 43
Muslim families in Israel 193–4
stoma care 45
Israel
multicultural setting 189–90
population statistics 190
Muslim families 193–4
religiosity of Jews 191
ultra-Orthodox families 190–3
Japan
depression 58
family considerations 14
prostate cancer 42
jargon 16
Judaism 283
religiosity in Israel 191
stoma care 45
ultra-Orthodox families 190–3
key points
bioethical challenges 209
cancer survivorship 245
communication and cultural considerations 18
care of end-of-life (EOL) care 266–7
families and care 196
gene therapy and testing 233
grief and bereavement 279
integrated interdisciplinary patient-centred care 94
international perspective on psycho-oncology 308
life-stage approach 162
neurocognitive effects of anticancer treatments 81
pediatric psycho-oncology 149
post-traumatic growth (PTG) 219
psychological intervention 105–6
psychopharmacological interventions 123–4
psychosocial and psychiatric disorders 67
psychosocial assessment and screening 34–5
rehabilitation 134
religious and spiritual issues 291
sexuality and gender 52
undeserved and minority populations 177
lamotrigine 122
language
jargon 16
non-native speakers 13
case study 15
interpreters 14
overcoming barriers 206–7
translations
Distress Thermometer 30–2
leukemia
age of onset 141
levetiracetam 122
libido, loss of men 41
women 42
life narrative therapy 263
life review therapy 159–60, 264
life-stage approach 161
access to care and psychosocial oncology services 156–7
attachment security 159
background 155–6
caregiving 161
case study 161–2
cognitive assessment and capacity 158
contextual factors 160–1
depression assessment 158
screening tools 158–9
effect of end-of-life (EOL) care 265–6
impact of cancer in old age 156
key points 162
psychosocial interventions 159–60
social support 159
spiritual well-being 161
suicide risk 255
lithium 121–2
logotherapy 263
lorazepam 252
anxiety disorders 61
loss, existential challenge 286
low- and medium-income countries (LMCs) 205
lung cancer prevalence 127
Lynch Syndrome 233
magical thinking 141
major depressive disorder (MDD) 57
see also depression
antidepressants 113
diagnosis 58–9
management and prognosis 59–60
prevalence 57–8
risk factors in cancer patients 59
Managing Cancer and Living Meaningfully (CALM therapy) 160
meaning 284
existential challenge 286
meaning-centred group psychotherapy (MCGP) 264
meaning-centred psychotherapy (MCP) 264
meaning-centred therapies 288–9
meditation 284
melatonin
delirium 57
Memorial Anxiety Scale for Prostate Cancer (MAX-PC) 23, 24
Memory and Attention Training (MAAT) 78
men
erectile dysfunction 41, 44
infertility 46
causes of in cancer 46–8
options 48
tissue banking and fertility preservation 48
libido, loss of 41
prostate cancer 41–2
men who have sex with men (MSM) 45
Mental Health Inventory-18 (MHI-18) 23, 24
methylphenidate 116
mianserin
delirium 57
Mindfulness Based Stress Reduction (MBSR) 284
minority populations see undeserved and minority populations
Index

post-traumatic growth (PTG) (Continued)
background
critique of PTG construct 213
historical overview and theoretical underpinnings
211–12
inventory 213
clinical case 212
cultural implications 218
key points 219
major issues
correlates of cancer-related PTG 213–14
distress and cancer-related PTG 214
non-Western countries 215–17
prevalence of cancer-related PTG 213
reasons for differences across cultures 214–15
Post-traumatic Growth Inventory (PGI) 145–6
Post-Traumatic Growth Inventory (PTGI) 213
post-traumatic stress disorder (PTSD)
antidepressants 114
children 143, 146
parents of childhood patients and survivors 147
US rates 172
prayer 283–4
pregabalin 122
pregnancy and cancer 49
Pre-operational Thinking 141
pre-school cancer sufferers 141–2
Profile of Mood States (POMS) 23, 24
Profile of Mood States-11 (POMS-11) 23, 24
Profile of Mood States-30 (POMS-30) 23, 24
prolonged grief disorder (PGD) 274
prostate cancer 41–2, 241
Prostate Cancer Foundation of Australia (PCFA) 302–3
prostate specific antigen (PSA)
recovery trajectory after treatment end 241
psychoeducation 132
psychological counselling 132
psychological distress
childhood cancer survivors 145
Psychological Distress Inventory (PDI) 23, 24
psychological intervention 97, 104
background 97–8
definition 98
evidence of efficacy 100–1
providers 98–100
types available 101
clinical case 104–5
key points 105–6
major issues 102
cost-effectiveness 103–4
efficacy 102
potential harm 103
psychiatric versus psychological models 102–3
psycho-oncology
communication, relevance of 12
introduction to 3–7
psychopharmacological interventions
109, 122–3
anticonvulsants 121–2
antidepressants
classification 114–16
indication in oncology settings 113–14
major drug interactions 112–13
overview 110–12
screening, monitoring and cautions for patients 116–17
special considerations 116
antipsychotic medications
classification 118–19
drug–drug interactions 120–1
indications 117–18
side effects and safety monitoring 119–20
anxiolytics 121
background 109
clinical case study 123
cultural implications 122
hypnotics 121
key points 123–4
major issues 109–10
mood stabilizers 121–2
stimulants
overview 110–12
psychosexual dysfunctions 64–5
psychosis 64
antipsychotic medication 118
Psychosocial Adaptation Tool 148
psychosocial interventions
elderly sufferers 159–60
psychosocial and psychiatric disorders 55
common disorders
adjustment disorders 61–2
anxiety disorders 60–1
delirium 55–7
major depressive disorder (MDD) 57–60
somatization and abnormal illness 62–4
cultural considerations 66–7
emergencies 66
key points 67
other disorders 64
alcoholism and substance abuse disorders 65–6
anticipatory nausea and vomiting (ANV) 65
psychosexual dysfunctions 64–5
psychosis 64
sleep disorders 64
psychosocial assessment and screening 21, 33–5
case study 33–4
genetic testing 224–5
family impacts 226–7
inconclusive test results 226
socio-cultural issues 228
testing negative 226
testing positive for genetic mutation 225–6
issues and evidence 21
availability of comparison data 25–6
cultural considerations 28–33
instruments 21–4
overall performance 27–8
reliability 24–5
screening performance 26–7
studies 21–4
validity 25
key points 34–5
Psychosocial Collaborative Oncology Group 298
Index 319

Psychosocial Screen for Cancer (PSSCAN) 23, 24
psychostimulants 116
psychotherapy 132
anxiety disorders 61
PTSD Checklist (PCL-C) 23, 24
quality of life
childhood cancer survivors 145
Question – Combined: Depressed and Lost Interest (Q-C:D&LI) 23, 24
Question – Single: Depressed (Q-S:D) 23, 24
Question – Single: Lost Interest (Q-S:LI) 23, 24
Questionnaire on Stress in Cancer Patients-Revised (QCS-R) 23, 24
quetiapine 117
delirium 57
hypotension 119
sedation 120
seizure risk 120
rehabilitation
cancer survivorship 127–8
case study 129
concept 129–30
health promotion 132
indication 131
International Classification of Functioning, Disability and Health (ICF) 128–9
key points 134
motivation 131
multiprofessional rehabilitation team 132–3
objectives 129–30
patient education 132
psychoeducation 132
psychological aspects 130
psychological interventions during rehabilitation 131–2
research 133–4
undeserved and minority populations 176–7
religious and spiritual issues 13, 281–2
clinical care delivery challenges 290
intersection of culture and religion 290–1
professional boundaries 290
role confusion 290
clinical issues for patient care 285
case studies 287, 288
interference with appropriate care 287–8
resources, need for 288
spiritual assessment by clinician 285–7
spiritual distress facing death 287
key points 291
major religions 282
Buddhism 282–3
Christianity 283
Confucianism 283
Hinduism 282
Islam 283
Judaism 283
Secular Humanism 283
Taoism 283
palliative (PC) and end-of-life (EOF) care 204
post-traumatic growth (PTG) 211–12
differences across cultures 214–15
prayer, spirituality and meaning 283
meaning 284
meditation 284
mystical experience 284–5
power of belief 284
spirituality 284
studies of prayer 283–4
therapeutic approaches
integrated care 289
meaning-centred therapies 288–9
religiously specific approaches/rituals 289
spiritual approach to atheists 290
spiritually integrated care 289
twelve-step recovery programme 289–90
well-being of elderly sufferers 161
risperidone 117
delirium 57
endocrine/metabolic side-effects 120
extrapyramidal symptoms (EPS) 119
hypotension 119
rituals 189, 289
Rotterdam Symptom Checklist (RSCL) 23, 24
Saudi Arabia
family considerations 14
schizophrenia 64
school-age cancer sufferers 142
screening see psychosocial assessment and screening
Screening for Distress 88
supportive quotes 93
Secular Humanism 283
spiritual approach 290
seizure risk 120
selective serotonin reuptake inhibitors (SSRIs) 114–15
anxiety disorders 61
depression 59
used in psycho-oncology settings 111
Self-Deception Enhancement (SDE) Scale 145
serotonin syndrome 112
serotonin–norepinephrine reuptake inhibitors (SNRIs) 115
depression 59–60
used in psycho-oncology settings 111
sertraline 111
metabolism 114
pharmacological issues 113
sexual dysfunction
psychosexual 64–5
sexuality and gender 39–40
common aspects and cultural variables 40–1
future directions 51–2
gastrointestinal and bladder cancer 44–5
gynaecological tumours and breast cancer 42–4
infertility 46–8, 49
complementary and alternative medicine (CAM) 49
impact on quality of life 50
in vitro fertilisation (IVF) 49
sexuality and gender (Continued)
  options 48
  sociocultural aspects 46
  suggestions for clinicians 50–1
  tissue banking and fertility preservation 48
  key points 52
  pregnancy and cancer 49
  prostate cancer 41–2
  Short Confusional Assessment Method (CAM) 56
  siblings of childhood patients and survivors 147
  therapeutic intervention 149
  sleep disruption/disorders 64
  antidepressants 114
  antipsychotic medication 118
  grief and bereavement 277
  socioeconomic status (SES) 13
  somatization in cancer patients 62
  diagnosis 63
  management and prognosis 64
  prevalence 62–3
  spiritual suffering therapy 264
  spirituality see religious and spiritual issues

State-Trait Anxiety Inventory (STAI)
23, 24

Stevens–Johnson syndrome 122
stimulants
overview 110–12
stoma patients 44–5
substance abuse disorders 66
suicidal ideation
children 146
frequency 257–9
suicide 255–7
assessment 256
questions for patients and families 247
assisted 260–1
supportive–expressive therapies 159
SupportScreen program 90
real-time outputs 92
survivorship 127–8, 205
Switzerland
immigrant groups 168
sympathy card guidelines 275
Symptom Checklist-90-Revised (SCL-90-R) 23, 24

symptoms of acute stress (SAS)
140
symptoms of cancer sufferers 127, 240–1
tamoxifen
increased risk of death with paroxetine 59–60
recommended antidepressants 113
Taoism 283
temazepam 252
testicular sperm extraction (TESE) 48
tissue banking 48
toddler cancer sufferers 141
Tom Baker Cancer Centre (Canada)
88–90
Integrated Symptom Relief Service Referral Pathways 91
Personal Well-Being Checklist 89
Traditional Chinese Medicine (TCM) 177
Trail-Making Test 79
training in communication skills 16–17
Transcultural Model of Change 131
traumatic stress symptoms 143
trazodone 112, 252
anxiety disorders 61
delirium 57
pharmacological issues 113
side effects 115
tricyclic antidepressants (TCAs) 115
anxiety disorders 61
depression 60
used in psycho-oncology settings 111
twelve-step recovery programme 289–90

UK
cancer care spending 298
childhood cancer studies 145
high-risk groups 167
undeserved and minority populations 165
background 166

USA
agencies and institutions
advocating psycho-oncology 4–5
childhood cancer studies 144–5
communication issues
case study 15
interpreters 14–15
community response to IOM Report 301
future provision 301–2
high-risk groups 167
immigrant groups 168
infertility 51
sociocultural aspects 46
IOM Report 300–1
prostate cancer
African Americans 41
Chinese populations 41
PTSD rates 172
vaginal dryness 42
vaginismus 42
venlafaxine 111
depression 59
metabolism 115
pharmacological issues 113
vinca alkaloids 64
Vital Signs 84
Index

whole-person cancer care 83–4
interdisciplinary 90–4
women
breast cancer 42–4
gynaecological tumours 42–4
infertility 46
causes of in cancer 46–8
options 48
tissue banking and fertility preservation 48
libido, loss of 42
pregnancy and cancer 49
sexual dysfunction 44
sexuality 43
zaleplon 121
ziprasidone 117
zolpidem 121
zopiclone 121
Zung Self-Rating Depression Scale (ZSDS) 23, 24